Physician profile
Rachel Smith
NPI 1184518003
$2,726.99
in general payments reported to CMS, 2019-2025
26 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $287.43 | 2025 | Symbravo |
| Ucb, INC. | $274.10 | 2025 | Fintepla, Nayzilam, Zilbrysq |
| Lundbeck LLC | $236.11 | 2025 | Rexulti, Vyepti |
| Emd Serono, INC. | $222.54 | 2025 | Mavenclad |
| Biogen, INC. | $197.90 | 2025 | Leqembi, Tysabri, Vumerity |
| Pfizer INC. | $190.18 | 2025 | |
| Argenx US, INC. | $187.46 | 2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $147.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $140.27 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $123.68 | 2025 | Austedo Xr, Ajovy |
| Catalyst Pharmaceuticals, INC. | $105.80 | 2025 | |
| Mallinckrodt Hospital Products INC. | $80.67 | 2025 | Acthar |
| Eisai INC. | $80.14 | 2025 | |
| Tg Therapeutics, INC. | $77.00 | 2025 | |
| Acadia Pharmaceuticals INC | $74.69 | 2025 | Nuplazid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56.54 | 2025 | |
| Ani Pharmaceuticals, INC. | $36.92 | 2025 | Purified Cortrophin Gel |
| Csl Behring | $35.19 | 2025 | Hizentra |
| Ge Healthcare | $31.94 | 2025 | |
| Medtronic, INC. | $27.04 | 2025 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $26.94 | 2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $25.95 | 2025 | Xeomin, Inbrija, Ampyra |
| Alexion Pharmaceuticals, INC. | $21.94 | 2025 | Ultomiris |
| Amgen INC. | $17.34 | 2025 | Uplizna |
| Lilly USA, LLC | $16.20 | 2025 | Kisunla |
| Life Molecular Imaging Ltd | $5.23 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.